Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

1p36 deletion syndrome confirmed by fluorescence in situ hybridization and array-comparative genomic hybridization analysis

  • Kang, Dong Soo (Department of Pediatrics, Dankook University Hospital) ;
  • Shin, Eunsim (Department of Genome Research Center, Neodin Medical Institute) ;
  • Yu, Jeesuk (Department of Pediatrics, Dankook University Hospital)
  • Received : 2014.08.13
  • Accepted : 2014.10.23
  • Published : 2016.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Pediatric epilepsy can be caused by various conditions, including specific syndromes. 1p36 deletion syndrome is reported in 1 in 5,000-10,000 newborns, and its characteristic clinical features include developmental delay, mental retardation, hypotonia, congenital heart defects, seizure, and facial dysmorphism. However, detection of the terminal deletion in chromosome 1p by conventional G-banded karyotyping is difficult. Here we present a case of epilepsy with profound developmental delay and characteristic phenotypes. A 7-year-and 6-month-old boy experienced afebrile generalized seizure at the age of 5 years and 3 months. He had recurrent febrile seizures since 12 months of age and showed severe global developmental delay, remarkable hypotonia, short stature, and dysmorphic features such as microcephaly; small, low-set ears; dark, straight eyebrows; deep-set eyes; flat nasal bridge; midface hypoplasia; and a small, pointed chin. Previous diagnostic work-up, including conventional chromosomal analysis, revealed no definite causes. However, array-comparative genomic hybridization analysis revealed 1p36 deletion syndrome with a 9.15-Mb copy loss of the 1p36.33-1p36.22 region, and fluorescence in situ hybridization analysis (FISH) confirmed this diagnosis. This case highlights the need to consider detailed chromosomal study for patients with delayed development and epilepsy. Furthermore, 1p36 deletion syndrome should be considered for patients presenting seizure and moderate-to-severe developmental delay, particularly if the patient exhibits dysmorphic features, short stature, and hypotonia.

Keywords

References

  1. Gajecka M, Mackay KL, Shaffer LG. Monosomy 1p36 deletion syndrome. Am J Med Genet C Semin Med Genet 2007;145C:346-56. https://doi.org/10.1002/ajmg.c.30154
  2. Heilstedt HA, Ballif BC, Howard LA, Kashork CD, Shaffer LG. Population data suggest that deletions of 1p36 are a relatively common chromosome abnormality. Clin Genet 2003;64:310-6. https://doi.org/10.1034/j.1399-0004.2003.00126.x
  3. Shaffer LG, Lupski JR. Molecular mechanisms for constitutional chromosomal rearrangements in humans. Annu Rev Genet 2000;34:297-329. https://doi.org/10.1146/annurev.genet.34.1.297
  4. Shapira SK, McCaskill C, Northrup H, Spikes AS, Elder FF, Sutton VR, et al. Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet 1997;61:642-50. https://doi.org/10.1086/515520
  5. Giraudeau F, Taine L, Biancalana V, Delobel B, Journel H, Missirian C, et al. Use of a set of highly polymorphic minisatellite probes for the identification of cryptic 1p36.3 deletions in a large collection of patients with idiopathic mental retardation. J Med Genet 2001;38:121-5. https://doi.org/10.1136/jmg.38.2.121
  6. Riegel M, Castellan C, Balmer D, Brecevic L, Schinzel A. Terminal deletion, del(1)(p36.3), detected through screening for terminal deletions in patients with unclassified malformation syndromes. Am J Med Genet 1999;82:249-53. https://doi.org/10.1002/(SICI)1096-8628(19990129)82:3<249::AID-AJMG10>3.0.CO;2-8
  7. Rosenfeld JA, Crolla JA, Tomkins S, Bader P, Morrow B, Gorski J, et al. Refinement of causative genes in monosomy 1p36 through clinical and molecular cytogenetic characterization of small interstitial deletions. Am J Med Genet A 2010;152A:1951-9. https://doi.org/10.1002/ajmg.a.33516
  8. Heilstedt HA, Ballif BC, Howard LA, Lewis RA, Stal S, Kashork CD, et al. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am J Hum Genet 2003;72:1200-12. https://doi.org/10.1086/375179
  9. Heilstedt HA, Burgess DL, Anderson AE, Chedrawi A, Tharp B, Lee O, et al. Loss of the potassium channel beta-subunit gene, KCNAB2, is associated with epilepsy in patients with 1p36 deletion syndrome. Epilepsia 2001;42:1103-11.
  10. Kurosawa K, Kawame H, Okamoto N, Ochiai Y, Akatsuka A, Kobayashi M, et al. Epilepsy and neurological findings in 11 individuals with 1p36 deletion syndrome. Brain Dev 2005;27:378-82. https://doi.org/10.1016/j.braindev.2005.02.004
  11. Bahi-Buisson N, Guttierrez-Delicado E, Soufflet C, Rio M, Daire VC, Lacombe D, et al. Spectrum of epilepsy in terminal 1p36 deletion syndrome. Epilepsia 2008;49:509-15. https://doi.org/10.1111/j.1528-1167.2007.01424.x
  12. Wang XB, Funada M, Imai Y, Revay RS, Ujike H, Vandenbergh DJ, et al. rGbeta1: a psychostimulant-regulated gene essential for establishing cocaine sensitization. J Neurosci 1997;17:5993-6000. https://doi.org/10.1523/JNEUROSCI.17-15-05993.1997
  13. Windpassinger C, Kroisel PM, Wagner K, Petek E. The human gamma-aminobutyric acid A receptor delta (GABRD) gene: molecular characterisation and tissue-specific expression. Gene 2002;292:25-31. https://doi.org/10.1016/S0378-1119(02)00649-2
  14. Atanasoski S, Notterpek L, Lee HY, Castagner F, Young P, Ehrengruber MU, et al. The protooncogene Ski controls Schwann cell proliferation and myelination. Neuron 2004;43:499-511. https://doi.org/10.1016/j.neuron.2004.08.001
  15. Edwards TJ, Sherr EH, Barkovich AJ, Richards LJ. Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. Brain 2014;137(Pt 6):1579-613. https://doi.org/10.1093/brain/awt358